[1] 江 红,李佩章,劳 明. 血清LDH 和β2-MG 水平与非霍奇金淋巴瘤的预后关系[J].医学研究杂志,2008,37(10) : 91-92.
[2] 任 丽,陈 瑛. 非霍奇金淋巴瘤实验诊断进展[J].国外医学临床生物化学与检验学分册,2005,26(3): 151-153.
[3] Eissa LA, Esmaeel MI. Relevance of some serum biomarkers(E cadherin, GAGs & MDA) in patients with diffuse large B-cell lymphoma [J]. Pak J Pharm Sci,2008, 21(1): 29-35.
[4] Rustin GJ, Vergote I, Eisenhauer E, et al. Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG) [J]. Int J Gynecol Cancer, 2011,21(2): 419-423.
[5] Yip GW, Smollich M, Gtte M. Therapeutic value of glycosaminoglycans in cancer [J]. Mol Cancer Ther, 2006,5(9):2139-2148.
[6] 卢桥发,王启明,甄海宁,等.联合检测血浆中GSH-PX、MDA及肿瘤蛋白对肺癌筛检的Bayes判别分析[J]. 肿瘤防治研究,2005,32(11):723-725.
[7] Lu R, Jiang M,CHEN Z, et al. Lactate dehydrogenase 5 expression in non-hodgkin lymphoma is associated with the induced hypoxia regulated protein and poor prognosis [J]. PLoS One, 2013, 8(9):e74853.
[8] Kopper L, Timar J, Kovalszky I, et al. Epitopes of cartilage core proteins and GAG pattern in human non-Hodgkin lymphoma xenografts[J]. In Vivo,1990, 4(2):149-152.
[9] 古爱虎,寇克韧,王 勇,等. 非霍奇金淋巴瘤患者血清LDH与β2 -MG 检测及其临床意义[J].中国临床新医学,2013,6(3): 221-223.
[10] 陈 芳,曹方方,张继红,等.β2微球蛋白与乳酸脱氢酶对非霍奇金淋巴瘤治疗效果的判断价值[J].中国全科医学, 2011,114(36): 4160-4163.